

CLINICAL PATHWAY: COVID-19 Outpatient Therapies For Providers Requesting Administration at CT Children's

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Patient may meet criteria for outpatient COVID-19 therapy (including monoclonal antibody infusions, prophylaxis, PO treatments, etc) under Emergency Use Authorization or FDA approved medication

Initial Assessment by Requesting Provider:

- Requesting provider must, at minimum:
 - Make a best effort to confirm all inclusion criteria met under the EUA
 - Provide basic information about medication, that it is an unapproved drug authorized for use under Emergency Use Authorization (EUA) and discuss if there are any alternatives available
 - At minimum, obtain consent that patient/family would like to proceed if Infectious Disease approval is given

Requesting Provider to Obtain Approval for Medication Administration/Dispensing at CT Children's:

- Contact Dr. John Schreiber (Infectious Disease Interim Division Head) or, if not available, Dr. Juan Salazar (Physician-In-Chief) via Voalte or One Call at 833-226-2362 (if external provider)
- **Requesting Provider MUST provide the following information:**
 - Name, DOB
 - *If not a CT Children's patient:* provide best contact number and recent weight
 - Brief explanation for requesting monoclonal (i.e., what is the high risk criteria)
 - First positive covid test/symptoms or last exposure
- **Once approval is obtained:** Infectious Disease will take over care from requesting provider
 - Exception: Heme/onc will be managed by their own division once approval obtained

CT Children's Role:

- CT Children's Infectious Disease will:
 - Discuss "Fact Sheet for Patients, Parents and Caregivers" and any further questions family might have
 - Discuss alternatives and that medication is authorized under EUA
 - Confirm consent to treat with medication
 - Order medication
- If infusion or IM medication: Sedation suite to schedule and call family to discuss specifics for the day (including parking, etc).
- If PO medication: Infectious Disease will coordinate clinic visit/medication distribution

Post Treatment Recommendations – Requesting Provider Role

- **Post infusion care:**
 - Follow up with the patient to monitor for ongoing symptoms, worsening, etc.
 - Monitor for side effects for at least 1 week and report them according to EUA instructions. Specific side effects are listed in each EUA
 - For monoclonal antibodies, staying well hydrated will help mitigate minor side effects
- **If infected with COVID-19:**
 - Ensure patient continues to adhere to CDC guidelines on isolation/quarantine
 - Make note of exercise limitations post COVID infection. See [Cardiology Return to Play Algorithm](#) on CT Children's Clinical Pathway site.
- **Other Considerations:**
 - Make note of when patients are eligible for COVID-19 vaccination and the restrictions outlined by the EUA
 - Make note of what new medications are started while receiving ongoing therapies and if they will adversely interact with one another. See specific EUA for details.

CONTACTS: JUAN SALAZAR, MD | JOHN SCHREIBER, MD | GRACE HONG, APRN
This pathway is subject to change, based on evolving recommendations from the CDC and CT DPH.

LAST UPDATED: 01.20.22

